SB 247083
endothelin-A receptor antagonist
Also Known As:
(E)-(1-butyl-5-(2-(2-carboxyphenyl)methoxy-4-chlorophenyl)-1H-pyrazol-4-yl)-2-(5-methoxydihydrobenzofuran-6-yl)methyl-2-propionic acid
Networked: 1
relevant articles (1 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
| 1. | Pulmonary Hypertension
|
| 2. | Hypoxia (Hypoxemia)
01/01/1999
- " In addition, the effects of the selective ETA receptor antagonist, SB 247083, and the selective ETB receptor antagonist, A-192621 (3.6 or 10.8 mg/day, ip), were compared against hypoxia-induced increases in pulmonary artery pressure and plasma ET concentrations. " 01/01/1999
- " SB 247083, but not A-192621, inhibited hypoxia-induced pulmonary hypertension, whereas A-192621, but not SB 247083, significantly exacerbated hypoxia-induced increases in ET concentrations, suggesting that hypoxia-induced pulmonary pressor responses are mediated via ETA receptor activation, while ETB receptor blockade may alter clearance of hypoxia-induced elevated plasma ET. "
|
|
Related Drugs and Biologics